Research programme: synthetic tolerogenic vaccines - Selecta Biosciences

Drug Profile

Research programme: synthetic tolerogenic vaccines - Selecta Biosciences

Alternative Names: SEL-701; t2SVP vaccines

Latest Information Update: 25 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Selecta Biosciences
  • Class Cancer vaccines; Parasitic vaccines; Synthetic vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cervical cancer; Chlamydial infections; Head and neck cancer; Malaria
  • Research Autoimmune disorders; Type 1 diabetes mellitus

Most Recent Events

  • 18 Jun 2015 Mucosal vaccines of Selecta Biosciences is available for licensing as of 25 Jul 2015. www.selectabio.com
  • 18 Jun 2015 Preclinical trials in Chlamydial infections (Prevention) in USA (Parenteral)
  • 23 Dec 2014 Selecta Biosciences receives a $US3.2 million grant from Skolkova Foundation for SVP immunotherapy development in HPV-associated cervical cancer and head and neck cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top